Cell & Gene Therapy Clinical Trial Services Market - By Service (Clinical Trial Design & Planning), Phase, Indication, Therapy Type (Gene, Cell, Gene Modified Cell Therapy), End-use (Pharmaceutical & Biotechnology, CRO) - Global Forecast (2024 ? 2032)

Market Report | 2024-05-06 | 209 pages | Global Market Insights

AVAILABLE LICENSES:

- Single User $4850.00
- Multi User $5350.00
- Enterprise User $8350.00

Report description:

Global Cell & Gene Therapy Clinical Trial Services Market size will expand at a 10.8 CAGR from 2024 to 2032, attributed to technological upgrades, such as CRISPR-Cas9 and viral vectors, in line with supportive regulatory environments. These innovations enhance therapeutic potential and streamline approval processes, stimulating increased research and trial activities. With regulatory agencies like the FDA facilitating faster approvals for groundbreaking therapies, there is a growing momentum among biotech firms and pharmaceutical companies to invest in and accelerate the development of novel treatments, fueling market growth.

For instance, in June 2023, the FDA launched a new office to handle a surge in cell and gene therapy submissions, including potential approvals for the first CRISPR therapy and gene therapy for Duchenne muscular dystrophy. This development signifies heightened regulatory activity and industry momentum, stimulating growth opportunities for service providers supporting these trials, ranging from patient recruitment to regulatory compliance and data management.

The cell amp gene therapy clinical trial services industry is fragmented based on service, phase, indication, therapy type, end-use, and region.

The neurology segment will garner remarkable gains through 2032, spurred by the pressing need for effective treatments for neurological disorders. With conditions like Parkinson's, Alzheimer's, and ALS driving research, there is a substantial investment in therapies targeting these areas. Clinical trials in neurology benefit from specialized expertise, robust patient recruitment networks, and regulatory support, making it a focal point for innovation. Advances in gene editing and cell therapies offer promising avenues for addressing unmet medical needs, further bolstering this segment's prominence.

The academic and research institutions segment will see a considerable surge by 2032, owing to their pivotal role in pioneering

innovative therapies and conducting early-stage trials. These institutions possess extensive expertise, infrastructure, and access to patient populations critical for advancing research. Collaborations with biotech firms and government funding bolster their capabilities. As demand grows for cutting-edge therapies, academic and research institutions will conduct essential clinical trials that validate the safety and efficacy of cell and gene therapies.

Asia Pacific cell amp gene therapy clinical trial services market share will experience a notable CAGR between 2024 and 2032 due to increasing investments in healthcare infrastructure, rising prevalence of genetic disorders, and supportive regulatory environments. The region's diverse patient population and lower operational costs attract global biotech and pharmaceutical firms to conduct clinical trials. As countries like China, Japan, and South Korea advance in biotechnology and genetic research, Asia Pacific will stand as a key contributor to the expansion of the global cell amp gene therapy clinical trial services industry.

Table of Contents:

Cell & Gene Therapy Clinical Trial Services Market - By Service (Clinical Trial Design & Planning), Phase, Indication, Therapy Type (Gene, Cell, Gene Modified Cell Therapy), End-use (Pharmaceutical & Biotechnology, CRO) - Global Forecast (2024 ? 2032)

Market Report | 2024-05-06 | 209 pages | Global Market Insights

To place an Order with Scotts International:

- - Print this form
- - Complete the relevant blank fields and sign
- - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	$4850.00
	Multi User	$5350.00
	Enterprise User	$8350.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*		Phone*	
First Name*		Last Name*	
Job title*			
Company Name*		EU Vat / Tax ID / NIP number*	
Address*		City*	
Zip Code*		Country*	

Date	2026-02-17
Signature	